Tsolakis N, et al. - Researchers analyzed asthmatics (N = 408; age 10-35 years) using the multi-allergen tests Phadiatop and fx5 (ImmunoCAP), to determine a clinically useful level of IgE sensitization for ruling out type 2 asthma. Two groups evolved based on IgE-antibody concentrations: ≥0.35 kU_A/L for at least one test or <0.35 kU_A/L for both tests. Subsequent classification of the latter group was as follows: IgE 0.10-0.34 kU_A/L and IgE < 0.10 kU_A/L. Univariate analyses revealed the association of at least one type 2 marker with each asthma outcome in subjects with IgE ≥0.35 kU_A/L. Young asthmatics with IgE antibodies <0.35 kU_A/L, but not those with IgE < 0.10 kU_A/L, exhibited clinically relevant elevation of type 2 biomarkers. Defining non-type 2 asthma via sensitive IgE-antibody measurement appeared possible.